Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/27/2852896/0/en/Vidac-Pharma-receives-Japanese-Patent-Office-Notice-of-Allowance-for-VDA-1275-cancer-drug-candidate.html
https://www.globenewswire.com//news-release/2024/03/12/2844278/0/en/Vidac-Pharma-secures-approval-for-next-phase-of-clinical-study-of-lead-asset-in-Cutaneous-T-Cell-Lymphoma.html
https://www.globenewswire.com//news-release/2024/02/19/2831055/0/en/Vidac-Pharma-presents-high-efficacy-in-multiple-solid-tumor-models-for-its-next-generation-cancer-drug-candidate-and-synergy-with-standard-of-care-treatment-in-liver-cancer-organoi.html
https://www.globenewswire.com/news-release/2024/01/29/2818489/0/en/Vidac-Pharma-reports-positive-interim-Phase-2a-data-in-orphan-disease-cutaneous-T-cell-lymphoma-CTCL-with-lead-asset-VDA-1102.html
https://www.globenewswire.com//news-release/2023/12/19/2798228/0/en/Vidac-Pharma-to-conduct-Phase-2b-study-for-actinic-keratosis-therapeutic-candidate-VDA-1102-with-CentroDerm.html